← Apnimed, Inc. (APMD) (APMD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Apnimed, Inc. (APMD) (APMD)
Pharmaceutical Preparations · market cap $969M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-08 (est.)
Earnings
Pipeline
20
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-08 (est.)Earningsimp 5/10
- 2027-02-28PDUFA · AD109 (Oxnimbi)imp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AD036 Dose 1 | Phase 2 | Obstructive Sleep Apnea |
| AD036 | Phase 2 | Sleep Disordered Breathing |
| AD113 | Phase 2 | Obstructive Sleep Apnea |
| AD128 | Phase 3 | Obstructive Sleep Apnea |
| Period A | Phase 2 | OSA |
| SAS0421a | Phase 2 | Sleep Apnea |
| Dosing 1: Atomoxetine | Phase 2 | Obstructive Sleep Apnea |
| AD109 | Phase 3 | OSA - Obstructive Sleep Apnea |
| AD182 | Phase 2 | Obstructive Sleep Apnea |
| AD109 dose1- A | Phase 2 | Obstructive Sleep Apnea |
| Mannitol | Phase 3 | Sleep Apnea, Obstructive |
| R-oxybutynin | Phase 2 | Obstructive Sleep Apnea |
| SAS0421b | Phase 2 | Sleep Apnea |
| AD504 | Phase 2 | Obstructive Sleep Apnea |
| Period B | Phase 2 | OSA |
| SAS0421c | Phase 2 | Sleep Apnea |
| AD313 | Phase 2 | Obstructive Sleep Apnea |
| Period C | Phase 2 | OSA |
| AD109 dose2- B | Phase 2 | Obstructive Sleep Apnea |
| AD036 Dose 2 | Phase 2 | Obstructive Sleep Apnea |
Price & technical context
3-month
—
6-month
—
12-month
—
52-wk range
$16.60–$32.55
vs 50-day MA
-21.7%
vs 200-day MA
—
Realized vol
93.2%
Max drawdown
-49.0%
Daily closes through 2026-10-23. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for APMD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.